Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Hepatitis C virus infection.

Björn Fischler1

  • 1Department of Pediatrics, Karolinska University Hospital, Huddinge, SE-141 86 Stockholm, Sweden. bjorn.fischler@karolinska.se

Seminars in Fetal & Neonatal Medicine
|February 27, 2007
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Antimicrobial Prophylaxis in Solid Organ and Hematopoietic Stem Cell Transplantation: A Survey Among Member Centers of the European Reference Network TransplantChild.

Pediatric transplantation·2026
Same author

Swedish guidelines for the management and treatment of patients with hepatitis D (delta) virus infection 2025.

Infectious diseases (London, England)·2025
Same author

Condition-Specific Growth Charts for Children With Alagille Syndrome.

JAMA network open·2025
Same author

Elevated Serum Bile Acids Predict Poor Liver Outcomes in Children With Alagille Syndrome: Results From the GALA Study Group.

Liver international : official journal of the International Association for the Study of the Liver·2025
Same author

Phenotypic Divergence of JAG1- and NOTCH2-Associated Alagille Syndrome & Disease-Specific NOTCH2 Variant Classification Guidelines.

Liver international : official journal of the International Association for the Study of the Liver·2025
Same author

Multicenter Study on Early Predictors of Biliary Atresia Outcomes.

Journal of pediatric surgery·2025

Chronic hepatitis C infection affects children globally, with mother-to-child transmission risks around 5%. Antiviral treatments show promise, but pediatricians must monitor interferon

Area of Science:

  • Pediatric Infectious Diseases
  • Hepatology
  • Virology

Background:

  • Chronic hepatitis C infection prevalence in children ranges globally from 0.1% to 15%, with higher rates in endemic regions like Africa.
  • Mother-to-child transmission of hepatitis C virus (HCV) occurs in approximately 5% of cases, with limited current preventative strategies.
  • While liver damage progression in infected children is typically slow, it can accelerate over 15-20 years or with co-existing chronic conditions.

Purpose of the Study:

  • To review the current understanding of chronic hepatitis C infection in the pediatric population.
  • To discuss the implications of vertical transmission and the need for testing in newborns.
  • To evaluate the efficacy and considerations of antiviral treatment in children with hepatitis C.

Main Methods:

Related Experiment Videos

  • Literature review of studies on pediatric hepatitis C prevalence, transmission, and treatment.
  • Analysis of data regarding disease progression and risk factors for severe liver damage.
  • Evaluation of existing antiviral treatment regimens, including interferon and ribavirin, in pediatric patients.

Main Results:

  • Hepatitis C infection affects children worldwide, with significant prevalence in certain areas.
  • Vertical transmission is a primary concern, necessitating testing for all infants born to infected mothers.
  • Antiviral treatments, particularly interferon and ribavirin combinations, demonstrate effectiveness comparable to adults, though interferon's impact on growth requires careful pediatric monitoring.

Conclusions:

  • All infants born to mothers with hepatitis C should be tested for the virus.
  • Antiviral therapy is important for managing chronic hepatitis C in children, especially those with risk factors for advanced liver disease.
  • Pediatricians must carefully consider the growth-related side effects of interferon when initiating treatment in children.